441 related articles for article (PubMed ID: 32926318)
1. Current status and future perspectives of immunotherapy in bladder cancer treatment.
Wu Z; Liu J; Dai R; Wu S
Sci China Life Sci; 2021 Apr; 64(4):512-533. PubMed ID: 32926318
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in nonmuscle invasive bladder cancer: current and emerging treatments.
Gupta M; Kates M; Bivalacqua TJ
Curr Opin Oncol; 2019 May; 31(3):183-187. PubMed ID: 30893148
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
4. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
5. From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer.
Tambaro R; Napoli MD; Pisano C; Cecere SC; Attademo L; Rossetti S; Feroce F; Setola S; Califano D; Russo D; Spina A; Perdonà S; Izzo A; Pignata S
Immunotherapy; 2021 Jan; 13(1):67-77. PubMed ID: 33045887
[TBL] [Abstract][Full Text] [Related]
6. Future directions in bladder cancer immunotherapy: towards adaptive immunity.
Smith SG; Zaharoff DA
Immunotherapy; 2016; 8(3):351-65. PubMed ID: 26860539
[TBL] [Abstract][Full Text] [Related]
7. Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.
Meng MV; Gschwend JE; Shore N; Grossfeld GD; Mostafid H; Black PC
J Urol; 2019 Dec; 202(6):1111-1119. PubMed ID: 31042108
[TBL] [Abstract][Full Text] [Related]
8. [Cytokine therapy of superficial bladder carcinoma. Mechanisms of action and results of therapy].
Otto T; Kälble T
Urologe A; 1994 Nov; 33(6):540-6. PubMed ID: 7817454
[TBL] [Abstract][Full Text] [Related]
9. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
10. Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.
Luo Y; Henning J; O'Donnell MA
Clin Dev Immunol; 2011; 2011():728930. PubMed ID: 21941579
[TBL] [Abstract][Full Text] [Related]
11. Current status and future directions of the use of novel immunotherapeutic agents in bladder cancer.
Lenfant L; Aminsharifi A; Seisen T; Rouprêt M
Curr Opin Urol; 2020 May; 30(3):428-440. PubMed ID: 32141936
[TBL] [Abstract][Full Text] [Related]
12. [Immunotherapy and bladder cancer].
Lenfant L; Rouprêt M
Biol Aujourdhui; 2018; 212(3-4):81-84. PubMed ID: 30973136
[TBL] [Abstract][Full Text] [Related]
13. [Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments].
Todenhöfer T; Boegemann M
Urologe A; 2020 Jul; 59(7):810-816. PubMed ID: 32468092
[TBL] [Abstract][Full Text] [Related]
14. Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder.
Kresowik TP; Griffith TS
Immunotherapy; 2009 Mar; 1(2):281-8. PubMed ID: 20046960
[TBL] [Abstract][Full Text] [Related]
15. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.
Kamat AM; Li R; O'Donnell MA; Black PC; Roupret M; Catto JW; Comperat E; Ingersoll MA; Witjes WP; McConkey DJ; Witjes JA
Eur Urol; 2018 May; 73(5):738-748. PubMed ID: 29055653
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer.
Alexandroff AB; Nicholson S; Patel PM; Jackson AM
Immunotherapy; 2010 Jul; 2(4):551-60. PubMed ID: 20636008
[TBL] [Abstract][Full Text] [Related]
17. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.
Miyazaki J; Onozawa M; Takaoka E; Yano I
Int J Urol; 2018 May; 25(5):405-413. PubMed ID: 29506322
[TBL] [Abstract][Full Text] [Related]
18. [Update 2016 - Immunotherapy for urothelial carcinoma].
Retz M; Gschwend JE; Schmid SC
Urologe A; 2016 Feb; 55(2):246-52. PubMed ID: 26767648
[TBL] [Abstract][Full Text] [Related]
19. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine.
Kawai K; Miyazaki J; Joraku A; Nishiyama H; Akaza H
Cancer Sci; 2013 Jan; 104(1):22-7. PubMed ID: 23181987
[TBL] [Abstract][Full Text] [Related]
20. Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Mukherjee N; Svatek RS; Mansour AM
Urol Oncol; 2018 Mar; 36(3):103-108. PubMed ID: 29429897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
